Etubics Corporation is a clinical stage biotechnology company focused on developing immunotherapeutics for the treatment of cancer and vaccines against infectious diseases.
The Company has a pipeline of product candidates based on our proprietary, advanced generation viral vector platform – the Etubics Platform – to generate both T cell mediated and antibody responses and its complimentary manufacturing human-based cell line. The Company’s principal product, ETBX-011, has completed Phase 1/2 clinical trials in metastatic colorectal cancer patients. ETBX-011 targets carcinoembryonic antigen (CEA) which is expressed in many types of cancer and we believe the product has broad clinical application.
In addition, the Company is manufacturing an immunotherapeutic that is directed against HER2/neu (ETBX-021). This product candidate may soon be employed in Phase 1 clinical trials for the treatment of patients with HER2+ breast cancer. Furthermore, the Company has a collaboration agreement with Duke University, Durham, North Carolina for the development of a HER3 based breast cancer immunotherapeutic (ETBX-031) which is moving forward to clinical trials. Etubics Corporation also collaborates with Sanford Cancer Center, Sioux Falls, South Dakota on the development of a product candidate that targets human papilloma virus (HPV) for the treatment of HPV induced cancers such as head and neck and cervical (ETBX-041). In addition, the Company is developing vaccines to combat infectious diseases and emerging pathogens, including a universal influenza vaccine (ETBX-051). Etubics Corporation was founded in 2003 and is headquartered in Seattle, Washington.
We have brought our first technology from “bench to bedside” for under $10 million.
Financing of Etubics and its underlying technology from inception to date has been accomplished through investments from individuals close to the Company and previous and current competitive National Institutes of Health (NIH) grants and contracts, which represent millions of dollars. Of this, the majority has been, or is being, invested through non-dilutive grants to pre-clinical data for of the technology and move our first product through clinical trials and into FDA registration for the treatment of colorectal cancers.
In October, 2015, the Company received an investment of $17 million from NantCell, Inc., and one other investor to advance our clinical programs.
Etubics has been funded primarily through non-dilutive, peer-reviewed grants and contracts received from various government agencies.
Maintain high value funded R&D alliances
Leverage the value of multiple development programs: cell lines and drug delivery systems
Expand pipelines of novel immunotherapy and vaccine candidates
License product opportunities
Decrease capital market risks by leveraging strategic partners for critical paths:
- Regulatory and clinical
- Marketing & sales
- Non-dilutive NIH grants and contracts
Etubics Fact Sheet
- Initiated pre-clinical studies in 2006
- Developing commercial prophylactic vaccines and immunotherapy products
- Corporate headquarters in Seattle, Washington
- Completed Phase I/II human clinical trials for ETBX-011, an immunotherapy for colon cancer patients
- Preparing to advance to Phase III pivotal trials for its lead product, ETBX-011